Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:5.99.1.2 (topoisomerase)
 9,166 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We cloned MAK11, MAK18, and MKT1 utilizing their genetic map positions. The MAK11 gene is close to CDC16 on chromosome XI. Both genes were cloned on a single 7-kb fragment, and both have now been sequenced. The MAK18 gene is located close to PET3 on chromosome VIII. A large plasmid carrying PET3 was obtained from R. Elder and R.E. Esposito and was found to also have the MAK18 gene. The MAK16 gene has been subcloned and sequenced starting with a clone provided by J. Crowley and D. Kaback. The MKT1 gene was mapped near the gene for topoisomerase II. The topoisomerase II clone was used as the starting point for chromosome-walking to isolate MKT1. A deletion-insertion mutation (disruption) of MKT1 results in an inability to maintain M2, but does not affect M1 or L-A maintenance. Clones of SKI3 and SKI8 were selected using the cold sensitivity for cell growth of ski- M1 strains. The SKI8 gene was disrupted and found to be nonessential for cell growth in the absence of M double-stranded RNA (dsRNA). The SKI3 and SKI8 genes were mapped using these clones. We have also obtained other clones suppressing the pathology caused by the high M titer in ski- strains. These clones are not the SKI genes themselves but somehow avoid the growth defect without repressing M copy number.
 ...
PMID:Molecular characterization of chromosomal genes affecting double-stranded RNA replication in Saccharomyces cerevisiae. 355 12

The epidermal growth factor receptor (EGFR)-src-signal transducers and activators of transcription 3 (STAT3) oncogenic pathway plays a central role in tumorigenesis and is involved not only in cell transformation but also in tumor escape to genotoxic treatments. Despite its importance, the molecular mechanisms by which this signaling pathway induces resistance to DNA damage remain most of the time to be characterized. In this study, we show that the EGFR-src pathway is activated in response to topoisomerase I inhibition. After treatment, this signaling cascade induced the activation of STAT3 and the binding of the transcription factor to the promoter of the Eme1 gene. Eme1 is an endonuclease involved in the processing of DNA damage after topoisomerase I inhibition. These results suggest a model by which the STAT3-mediated activation of Eme1 prevents DNA damage and enhances cell survival in response to topoisomerase inhibition. This survival pathway was inhibited by a combined treatment with a src inhibitor, SKI, and with cetuximab, a monoclonal antibody directed against the EGFR that is widely used in the treatment of colorectal cancers. We therefore propose that the benefit of anti-EGFR therapy relies on an increase of DNA damage generated by topoisomerase I inhibition.
 ...
PMID:The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. 1824 83